Abstract：
BACKGROUND: Trichorhinophalangeal syndrome type 1 (TRPS1) has emerged as a reliable immunohistochemistry (IHC) marker for identifying breast origin in metastatic carcinomas. This study investigates the utility of TRPS1 IHC in non-breast cytology specimens.
METHODS: A retrospective search of our pathology database for the year 2021 identified fluids (pleural and peritoneal) and liver, lung and bone fine needle aspirations (FNAs) with surgical follow-up confirming non-breast metastatic carcinomas. Cell blocks from cases with sufficient neoplastic cells underwent immunostaining using a rabbit polyclonal antibody against human TRPS1. Cases lacking tumor on deeper levels after the original work-up were excluded from the study. Two pathologists independently interpreted the TRPS1 staining.
RESULTS: Of 136 cases assessed, 31 (22.79%) exhibited positive TRPS1 staining, while 105 (77.21%) were nonreactive. Positivity rates were observed in tumors of Mullerian cell origin, gastrointestinal tract (GIT), and lung origin at 28.85%, 25%, and 21.57%, respectively. Of the tumors of Mullerian cell origin 10 (66.67%) were serous carcinomas, 4 (26.67%) were endometrioid carcinomas, and one (6.67%) was a clear cell carcinoma. Lung tumors comprised seven (63.64%) squamous cell carcinomas and four (36.36%) adenocarcinomas, while the gastrointestinal tumors consisted of 14 (80%) adenocarcinomas and one (20%) squamous cell carcinoma.
CONCLUSIONS: Although recognized as a sensitive marker for mammary carcinomas, TRPS1 immunostaining was also detected in Mullerian, lung, and GIT carcinomas. This highlights the significance of being cautious when depending solely on TRPS1 immunostaining to distinguish metastatic breast tumors.
METHODS: A retrospective search of our pathology database for the year 2021 identified fluids (pleural and peritoneal) and liver, lung and bone fine needle aspirations (FNAs) with surgical follow-up confirming non-breast metastatic carcinomas. Cell blocks from cases with sufficient neoplastic cells underwent immunostaining using a rabbit polyclonal antibody against human TRPS1. Cases lacking tumor on deeper levels after the original work-up were excluded from the study. Two pathologists independently interpreted the TRPS1 staining.
RESULTS: Of 136 cases assessed, 31 (22.79%) exhibited positive TRPS1 staining, while 105 (77.21%) were nonreactive. Positivity rates were observed in tumors of Mullerian cell origin, gastrointestinal tract (GIT), and lung origin at 28.85%, 25%, and 21.57%, respectively. Of the tumors of Mullerian cell origin 10 (66.67%) were serous carcinomas, 4 (26.67%) were endometrioid carcinomas, and one (6.67%) was a clear cell carcinoma. Lung tumors comprised seven (63.64%) squamous cell carcinomas and four (36.36%) adenocarcinomas, while the gastrointestinal tumors consisted of 14 (80%) adenocarcinomas and one (20%) squamous cell carcinoma.
CONCLUSIONS: Although recognized as a sensitive marker for mammary carcinomas, TRPS1 immunostaining was also detected in Mullerian, lung, and GIT carcinomas. This highlights the significance of being cautious when depending solely on TRPS1 immunostaining to distinguish metastatic breast tumors.
摘要：
背景：1型三鼻咽喉癌综合征（TRPS1）已成为一种可靠的免疫组织化学（IHC）标志物，用于识别转移癌的乳腺起源。这项研究调查了TRPS1IHC在非乳腺细胞学标本中的实用性。
方法：对我们2021年的病理学数据库进行回顾性搜索，确定了液体（胸膜和腹膜）和肝脏，肺和骨细针穿刺（FNA），并进行手术随访，确认非乳腺转移性癌。使用抗人TRPS1的兔多克隆抗体对具有足够肿瘤细胞的病例的细胞块进行免疫染色。在原始检查后缺乏更深层次肿瘤的病例被排除在研究之外。两名病理学家独立解释TRPS1染色。
结果：在评估的136例中，31例(22.79%)TRPS1染色呈阳性,105（77.21%）无反应性。在穆勒细胞起源的肿瘤中观察到阳性率，胃肠道（GIT），和肺起源为28.85%，25%,和21.57%，分别。在苗勒细胞起源的肿瘤中，有10例（66.67％）是浆液性癌，4例（26.67%）为子宫内膜样癌，1例(6.67%)为透明细胞癌。肺肿瘤包括7例（63.64%）鳞状细胞癌和4例（36.36%）腺癌，而胃肠道肿瘤包括14例(80%)腺癌和1例(20%)鳞状细胞癌。
结论：尽管被认为是乳腺癌的敏感标志物，TRPS1免疫染色也在Mullerian中检测到，肺，和GIT癌。这凸显了当仅依靠TRPS1免疫染色来区分转移性乳腺肿瘤时要谨慎的重要性。
方法：对我们2021年的病理学数据库进行回顾性搜索，确定了液体（胸膜和腹膜）和肝脏，肺和骨细针穿刺（FNA），并进行手术随访，确认非乳腺转移性癌。使用抗人TRPS1的兔多克隆抗体对具有足够肿瘤细胞的病例的细胞块进行免疫染色。在原始检查后缺乏更深层次肿瘤的病例被排除在研究之外。两名病理学家独立解释TRPS1染色。
结果：在评估的136例中，31例(22.79%)TRPS1染色呈阳性,105（77.21%）无反应性。在穆勒细胞起源的肿瘤中观察到阳性率，胃肠道（GIT），和肺起源为28.85%，25%,和21.57%，分别。在苗勒细胞起源的肿瘤中，有10例（66.67％）是浆液性癌，4例（26.67%）为子宫内膜样癌，1例(6.67%)为透明细胞癌。肺肿瘤包括7例（63.64%）鳞状细胞癌和4例（36.36%）腺癌，而胃肠道肿瘤包括14例(80%)腺癌和1例(20%)鳞状细胞癌。
结论：尽管被认为是乳腺癌的敏感标志物，TRPS1免疫染色也在Mullerian中检测到，肺，和GIT癌。这凸显了当仅依靠TRPS1免疫染色来区分转移性乳腺肿瘤时要谨慎的重要性。
